

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

POSITIVE PROFIT ALERT FOR THE SIX MONTHS ENDED 30 JUNE 2015

This announcement is made by the Company pursuant to Rule 13.09(2) of the Listing Rules and the Inside Information Provisions.

The Board wishes to inform the Shareholders and potential investors that based on the information currently available to the Company and the preliminary assessment by the Company's management with reference to the unaudited management accounts of the Group for the five months ended 31 May 2015, the Group expects approximately 50% year-on-year increase in its unaudited profit attributable to owners of the parent for the six months ended 30 June 2015.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

The announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Dawnrays Pharmaceutical (Holdings) Limited (the "**Company**") pursuant to Rule 13.09(2) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the inside information provisions (the "**Inside Information Provisions**") under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that based on the information currently available to the Company and the preliminary assessment by the Company's management with reference to the unaudited management accounts of the Company and its subsidiaries (collectively referred to as the "**Group**") for the five months ended 31 May 2015, the Group expects approximately 50% year-on-year increase in its unaudited profit attributable to owners of the parent for the six months ended 30 June 2015 ("**Profit**").

The increase in the Group's Profit in the first half of 2015 was primarily attributable to the increase in revenue of high-gross-profit-margin system specific medicines compared with the corresponding period of 2014, as the Group's continued efforts towards the enhancement in the Group's management control and the sales management as described in the Company's 2014 annual report.

The information contained in this announcement is only based on the information currently available to the Company and the preliminary assessment by the Company's management with reference to the unaudited management accounts for the five months ended 31 May 2015, which is subject to possible adjustments following further internal review, and is not based on any figure or information which has been reviewed by the Company's auditors or audit committee. Further details of the Group's performance will be disclosed in the interim results of the Group for the six months ended 30 June 2015 which are expected to be announced in August 2015.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman and Chief Executive Officer

Hong Kong, 2 July 2015

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Li Tung Ming; two non-executive directors, namely Mr. Leung Hong Man and Mr. Ede, Ronald Hao Xi; three independent non-executive directors, namely Mr. Pan Xue Tian, Mr. Choi Tat Ying Jacky and Mr. Lo Tung Sing Tony.

**For identification purpose only*